Abstract
Breast cancer (BC) in Oman affects younger women and has a more aggressive course. Clinical and biological variables like age, pregnancy, tumor size, type, grade, receptor expression and proliferation predict disease aggression but there is no direct predictor of metastasis except lymphovascular invasion. Epithelial-mesenchymal transition (EMT) is characterized by epithelial cells losing epithelial and acquiring mesenchymal morpho-immunophenotypic characteristics. In tumors, EMT-like transitions may signify a metastatic phenotype and have features in common with cancer stem cells (CSC) which show resistance to chemotherapy. This study aimed to identify EMT and CSC phenotypes in metastatic and non-metastatic breast cancer in Omani women and their association with conventional clinico-pathological predictors of BC. In a retrospective study of ninety-six Omani women with breast cancer, the association of age, pregnancy/lactation, tumor size, type, grade, ductal carcinoma insitu (DCIS), lymphovascular invasion, hormone/ HER2 receptor expression and Ki67 proliferation index (Ki67 PI) was tested with EMT/ CSC phenotype and metastasis. Young age ≤ 40 years, lymphovascular invasion and EMT had a strong association with metastasis; CSC approached significance. Vimentin expression in tumor cells, fibronectin and MMP-11 in stroma were reliable markers of EMT; dual EMT and CSC phenotype (Vim+/ CD44+/ CD 24−/low) had a strong association with apocrine variant, basal-like tumors and triple negative cancers. EMT had a strong association with Ki67 proliferation index (PI) and CSC with HER2-like tumors and distant metastasis. These select markers may be useful in metastasis-prediction in pre-treatment biopsies.
Similar content being viewed by others
References
Kalluri R, Weinberg RA (2009) The basics of epithelial–mesenchymal transition. J Clin Invest 119:1420–1428
Witz IP. The tumor microenvironment: the making of a paradigm. Tumor Microenvironment 2(1):S9-S17
Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890
Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 7(21):10123–10128
Orimo A, Gupta PB, Sgroi DC, Seisdedos A, Delauney T, Naem R et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 21(3):335–348
Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 4(6):818–829
Gupta GP, Massague J (2006) Cancer Metastasis: building a framework. Cell 127(4):679–695
Park CC, Bissell MJ, Barcellos-Hoff MH (2000) The influence of the microenvironment on the malignant phenotype. Mol Med Today 6:324–329
Sager R (1997) Expression genetics in cancer: shifting the focus from DNA to RNA. Proc Natl Acad Sci U S A 94:952–955
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749
Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A (2013) Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 3(1):7–15
Mani SA, Guo W, Liao MJ, Eaton EN, Ayannan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715
Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820–5828
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67(5):1979–1987
Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD (2011) A systems view of epithelial–mesenchymal transition signaling states. Clin Exp Metastasis 28:137–155
Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109:2784–2789
Tiwari N, Gheldof A, Tatari M, Christofori G (2012) EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22:194–207
Tomaskovik-Crook E, Thompsom EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11(6):213
Kimbung S, Kovaks A, Bendahl P-A, Malmstrom P, Ferno M, Hatschek T, Hedenfalk I (2013) Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol. doi:10.1016/j.molonc.2013.10.002
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106(33):13820–13825
Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY (2013) Tumor infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713. doi:10.1038/bjc.2013.634
Kumar S, Burney A, al-Ajmi A, al-Moundhri M (2011) Changing trends of breast cancer survival in Sultanate of Oman. J Oncol. doi:10.1155/2011/316243
Bharat A, Aft RL, Gao F, Margenthaler JA (2009) Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol 100(3):248–251. doi:10.1002/jso.21268
Colleoni M, Anders CK (2013) Debate: the biology of breast cancer in young women is unique. Oncologist 18(4):e13–e15. doi:10.1634/theoncologist.2013-0118
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual. Springer-Verlag, New York
Lakhani S (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer, Lyon
Elston CW, Ellis I O (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 19; 403-410. Author Commentary Histopathology 2002; 41(3A):151–2
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American society of clinical oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22:1736–1747
Glentis A, Gurchenkov V, Matic Vignjevic D (2014) Assembly, heterogeneity, and breaching of the basement membranes. Cell Adhes Migr 8(3):236–245
Pogány G, Timár F, Oláh J, Harisi R, Polony G, Paku S et al (2001) Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. Oncology 60(3):274–281
Harisi R, Kenessey I, Olah JN, Timar F, Babo I, Pogany G et al (2009) Differential inhibition of single and cluster type tumor cell migration. Anticancer Res 29(8):2981–2985
Nadir Y, Brenner B (2014) Heparanase multiple effects in cancer. Thromb Res 133(Suppl 2):S90–S94. doi:10.1016/S0049-3848(14)50015-1
Böger C, Warneke VS, Behrens HM, Kalthoff H, Goodman SL, Becker T, Röcken C (2014) Integrins αvβ 3 and α vβ 5 as prognostic, diagnostic, and therapeutic targets in gastric cancer. Gastric Cancer 18(4):784–795. doi:10.1007/s10120-014-0435-2
Harisi R, Jeney A (2015) Extracellular matrix as target for antitumor therapy. Onco Targets Ther 8:1387–1398. doi:10.2147/OTT.S48883
Jia Y, Chen Y, Wang Q, Jaysinghe U, Luo X, Wei Q et al. (2017) Exosome: emerging biomarker in breast cancer. Oncotarget. 2017 mar 29. doi: 10.18632/oncotarget.16684
Zeisberg M, Neilson EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119(6):1429–1437. doi:10.1172/JCI36183
Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548–558
Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H (2005) Transcriptional activation of integrin beta6 during the epithelial mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115:339–347
Raymond WA, Leong AS (1989) Vimentin--a new prognostic parameter in breast carcinoma? J Pathol 158:107–114
Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS (2010) AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res 70(19):7360–7364. doi:10.1158/0008-5472.CAN-10-1208
Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997
Lima JF, Nofech-Mozes S, Bayani J, John M, Bartlett S (2016) EMT in Breast Carcinoma—A Review. J Clin Med 5(7):65. Published online 2016 Jul 14. doi:10.3390/jcm5070065
Brabletz T, Jung A, Hermann K, Günther K, Hohenberger W, Kirchner T (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194:701–704
Christensen L (1992) The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS Suppl 26:1–39
Carpenter PM, Wang-Rodriguez J, Chan OT, Wilczynski SP (2008) Laminin 5 expression in metaplastic breast carcinomas. Am J Surg Pathol 32:345–353
Barrallo-Gimeno A, Nieto MA (2005) The snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132:3151–3161
Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T et al (2007) Up-regulation of gastric cancer cell invasion by twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 358:925–930
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601
Foroni C, Broggini M, Generali D, Damia G (2012) Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 38(6):689–697. doi:10.1016/j.ctrv.2011.11.001
Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H (2005) Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11:1154–1159
Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR et al (2011) Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32:650–658
Sharma P (2016) Biology and Management of Patients with Triple-Negative Breast Cancer. Oncologist 21(9):1050–1062. doi:10.1634/theoncologist.2016-0067
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y et al (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS one 11(6):e0157368. doi:10.1371/journal.pone.0157368
Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76
Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs 185:191–203
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679
Marcucci F, Ghezzi P, Rumio C (2017) The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells. Mol Cancer 16(1):3. doi:10.1186/s12943-016-0573-8
Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Lambe M (2011) Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomark Prev 20(9):1865–1872
Sung CO, Park CK, Kim SH (2011) Classification of epithelial-mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis. Mod Pathol 24:1060–1068
Ryu HS, Park DJ, Kim HH, Kim WH, Lee HS (2012) Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 43:520–528
Bae YK, Choi JE, Kang SH, Lee SJ (2015) Epithelial-mesenchymal transition phenotype is associated with Clinicopathological factors that indicate aggressive biological behavior and poor clinical outcomes in invasive breast cancer. J Breast Cancer 18(3):256–263. doi:10.4048/jbc.2015.18.3.256
Pomp V, Leo C, Mauracher A, Korol D, Guo W, Varga Z (2015) Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. Breast Cancer Res Treat 154(1):45–55
Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. J Pathol 136(1):219–227
Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138:592–603
Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R (2008) Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7:464–473
Shiyang W, Suyan L, Zhiming L, Jiefeng H, Xiaoyu P, Jing L et al (2015) Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One 10(4):e0123976. doi:10.1371/journal.pone.0123976
Tachtsidis A, McInnes LM, Jacobsen N, Thompson EW, Saunders CM (2016) Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis 33(6):521–550. doi:10.1007/s10585-016-9796-8
Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A et al (2017) HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. Tumour Biol 39(3):1010428317695028. doi:10.1177/1010428317695028
Acknowledgements
This paper is derived from research carried out at Sultan Qaboos University funded by Internal grant IG/MED/PATH/15. Technical laboratory assistance by Chief BMS Johanes Selva Kumar and secretarial support by Edna B Ranada is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lakhtakia, R., Aljarrah, A., Furrukh, M. et al. Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women. Cancer Microenvironment 10, 25–37 (2017). https://doi.org/10.1007/s12307-017-0194-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12307-017-0194-9